Literature DB >> 7535757

Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP-470, and mitomycin C on the growth and liver metastasis of human colon cancer.

H Konno1, T Tanaka, I Matsuda, T Kanai, Y Maruo, N Nishino, S Nakamura, S Baba.   

Abstract

Angiogenesis inhibitors have attracted considerable interest. The anti-tumor and anti-metastatic effects of TNP-470, an angiogenesis inhibitor, and mitomycin C (MMC), a representative anti-neoplastic agent, were investigated using a xenotransplanted human colon cancer, TK-4. Suturing of small pieces of TK-4 tumors to the cecal wall in nude mice (orthotopic transplantation) induced liver metastasis. Mice were randomly divided into 3 groups; a control group given saline solution, a group receiving TNP-470 and a group receiving MMC. TNP-470 was given s.c. on alternate days for 5 weeks from day 10 after cecal transplantation and MMC was administered intraperitoneally (i.p.) once a week from day 10 after cecal transplantation. MMC significantly inhibited cecal tumor growth. In the control group, liver metastases developed in 9 out of 10 mice, including 3 with more than 20 metastatic foci. Liver metastasis also developed in 8 out of 10 mice receiving MMC, 2 of which had many metastases. In contrast, liver metastasis developed in only 2 out of 8 mice in the TNP-470 group and neither of these animals had numerous metastases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535757     DOI: 10.1002/ijc.2910610221

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  The role of the vascular phase in solid tumor growth: a historical review.

Authors:  D Ribatti; A Vacca; F Dammacco
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  Inhibitory Effect of the Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl)fumagillol(TNP-470) on Tumor Growth and Metastasis of Murine Mammary Tumor Cell Line (JYG-B)Inoculated in Female Nude Mice.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

Review 3.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

4.  An ultra-metastatic model of human colon cancer in nude mice.

Authors:  F X Sun; A R Sasson; P Jiang; Z An; R Gamagami; L Li; A R Moossa; R M Hoffman
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

5.  Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.

Authors:  Niranjan Awasthi; Changhua Zhang; Anna M Schwarz; Stefan Hinz; Margaret A Schwarz; Roderich E Schwarz
Journal:  Mol Cancer Ther       Date:  2014-03-07       Impact factor: 6.261

6.  Fumagillin treatment of hepatocellular carcinoma in rats: an in vivo study of antiangiogenesis.

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Wen-Juei Jeng; Chi-Juei Jeng; Yi-Ching Wang; Shu-Ling Gu; Shin-Yun Tseng; Chien-Ming Chu; Chia-Hui Lin; Kuo-Ming Chang
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

7.  Angiogenesis inhibitor TNP-470 suppresses growth of peritoneal disseminating foci of human colon cancer line Lovo.

Authors:  Ying-Fang Fan; Zong-Hai Huang
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

8.  The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice.

Authors:  H J Bernsen; P F Rijken; H Peters; H Bakker; A J van der Kogel
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

9.  Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.

Authors:  Lin Jia; Mei-Hua Zhang; Shi-Zhen Yuan; Wen-Ge Huang
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

Review 10.  Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic.

Authors:  R M Hoffman
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.